PPARgamma agonists: a new strategy for antithrombotic therapy.
Smyth
S S
SS
Carolina Cardiovascular Biology Center, The University of North Carolina at Chapel Hill, NC 27599-7126, USA. ssmyth@med.unc.edu
Jennings
J L
JL
D003925:Diabetic Angiopathies / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D006943:Hyperglycemia / Q000150:complications / Q000188:drug therapy; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D047495:PPAR gamma / Q000819:agonists*; D000077205:Pioglitazone; D015539:Platelet Activation; D045162:Thiazolidinediones / Q000627:therapeutic use; D013927:Thrombosis / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control
D005343:Fibrinolytic Agents; D007004:Hypoglycemic Agents; D047495:PPAR gamma; D045162:Thiazolidinediones; D000077205:Pioglitazone